[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100526954":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":29,"centralContacts":30,"locations":36,"responsibleParty":54,"collaborators":29,"id":56,"slug":29,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":29,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":29,"enrollmentInfo":64,"targetDuration":29,"studyType":67,"phases":68,"briefSummary":71,"conditions":72,"keywords":29,"overallStatus":39,"whyStopped":29,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Shanghai Refreshgene Technology Co., Ltd.","INDUSTRY",[8,14,17,20],{"label":9,"type":10,"description":11,"interventionNames":12},"RRG001 Dose1","EXPERIMENTAL","Frequency of administration: one time injection.",[13],"Drug: RRG001",{"label":15,"type":10,"description":11,"interventionNames":16},"RRG001 Dose2",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"RRG001 Dose3",[13],{"label":21,"type":10,"description":11,"interventionNames":22},"RRG001 Dose4",[13],[24],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DRUG","RRG001","Administered via Subretinal injection. Dosage form: injection solution.",[9,15,18,21],null,[31],{"name":32,"role":33,"phone":34,"phoneExt":29,"email":35},"Xiaorong Li, Master","CONTACT","8602223346434","xiaorong.li@163.com",[37],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Tianjin Medical University Eye Hospital","RECRUITING","Tianjin","Tianjin Municipality","300384","China",{"type":45,"coordinates":46},"Point",[47,48],117.17667,39.14222,{"lat":48,"lon":47},[51],{"name":52,"role":33,"phone":34,"phoneExt":29,"email":53},"Li Xiaorong, Professor","xiaorli@163.com",{"type":55,"investigatorFullName":29,"investigatorTitle":29,"investigatorAffiliation":29,"oldNameTitle":29,"oldOrganization":29},"SPONSOR","100526954",false,"NCT06141460","Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)","A Phase I\u002FIIa, Dose-escalation and Dose-extension Study to Evaluate the Safety and Efficacy of Single Subretinal Injection of RRG001 in Subjects With Neovascular Age-related Macular Degeneration","Inclusion Criteria:\n\n* Subjects that are willing and able to follow study procedures.\n* Patinets ≥50 years old.\n* Clinically diagnosed with CNV secondary to nAMD.\n* BCVA of the study eye is ≥5 letters and ≤73 letters(Snellen 20\u002F800\\~20\u002F40), as well as that of the other eye ≥19 letters(Snellen 20\u002F400).\n* Responding to anti-VEGF\n\nExclusion Criteria:\n\n* Presence of any other eye diseases other than nAMD in study eye that would affect the treatment or confusing the interpretation of the study results , as judged by the investigator.\n* CNV or macular edema in the study eye secondary to any causes other than AMD.\n* Uncontrolled glaucoma.\n* Uncontrolled hypertension despite medication.\n* Pregnant or lactating women or individuals with reproductive potential who are unwilling to take effective contraception during the study period.","ALL","50 Years",{"count":65,"type":66},48,"ESTIMATED","INTERVENTIONAL",[69,70],"PHASE1","PHASE2","A Phase I\u002FIIa, Dose-escalation and Dose-expansion Study to Evaluate the Safety and Efficacy of Single Subretinal Injection of RRG001 in Subjects With Neovascular Age-related Macular Degeneration",[73],"Neovascular Age-related Macular Degeneration","2024-11-12",{"date":76,"type":77},"2024-11-14","ACTUAL",{"date":79,"type":77},"2023-12-12",{"date":81,"type":66},"2030-12-31",{"name":5,"class":6},1]